At the close of the recent quarter, Ampliphi Biosciences Corp. (NYSE MKT:APHB)‘s balance sheet demonstrated total assets worth $14.3M and debt of 598,000%. Compared to the previous period, the debt increased/decreased by falling.
Ampliphi Biosciences Corp.’s total liabilities closing the latest quarter was $7.65M.
Let’s look into the technical of the stock
The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction. Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.
The assets that the firm listed at the close of the recent quarter comprised cash balance of 2.2M%. Net operating cash from the previous quarter was $(3.3M), resulting in free cash flow of $(3.3M). Compared to the previous period, net change in case was $(3.51M).
The cash that Ampliphi Biosciences Corp. generated in the previous quarter stemmed from sales of 29,000%, which increased -2.66% in the same quarter, a year ago.
After considering other operating expenses, the firm closed with a net income figure. When that amount divided by the number of outstanding shares it closed up with EPS (earnings per share) of $(1.94). For perspective on how Ampliphi Biosciences Corp. reached at the EPS figure, shareholders should know that the firm closed the last quarter with diluted due shares of 1.68M.
Wall Street analysts reported investors should anticipate from Ampliphi Biosciences Corp. EPS of $ in the next quarter.
In addition to estimating the next quarter’s EPS, market analysts have weighed in on the stock of Ampliphi Biosciences Corp. regarding whether shareholders should view it as a SELL, BUY or HOLD.
